Welcome to our dedicated page for Gabelli Healthcare & WellnessRx Trust SEC filings (Ticker: GRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gabelli Healthcare & WellnessRx Trust filings document the formal disclosures of a Delaware statutory trust operating as a diversified closed-end management investment company. The records identify GRX common shares of beneficial interest registered on the New York Stock Exchange and describe governance matters handled through annual shareholder meeting proxy materials.
GRX filings also include material-event reports related to adviser and portfolio management continuity, including disclosures tied to GAMCO Investors, Gabelli Funds, LLC, and leadership responsibilities affecting the fund's investment management structure. The filing record is centered on fund governance, shareholder voting matters, registered securities, and adviser-related events.
Gabelli Healthcare & WellnessRx Trust reported that Christopher J. Jackson, who serves as Secretary, filed an initial statement of beneficial ownership of securities. The filing does not list any reportable transactions or holdings, indicating this is an administrative Form 3 establishing his insider reporting status.
Saba Capital Management, L.P., a ten percent owner of Gabelli Healthcare & WellnessRx Trust (GRX), reported a purchase of common stock. On 2026-08-14 it bought 1,203 shares at $9.86 per share in an open market or private transaction, bringing its reported indirect holdings to 2,119,604 shares.
Saba Capital Management, L.P., a ten percent owner of Gabelli Healthcare & WellnessRx Trust (GRX), reported purchasing 200 shares of common stock on 2026-08-11 at $9.93 per share in an open market or private transaction. Following this indirect acquisition, Saba Capital’s reported holdings increased to 2,118,401 shares of GRX common stock.
The Gabelli Healthcare & WellnessRx Trust reported a leadership update following a medical incident involving Trustee and Chief Investment Officer Mario J. Gabelli, who was hospitalized on March 19, 2026 and is recovering, though his return date is unknown. GAMCO’s long-standing succession plan was implemented on March 22, 2026, naming Christopher J. Marangi as President of GAMCO. Day-to-day operations of GAMCO will continue to be led by co-CEO Douglas R. Jamieson and Mr. Marangi, while Gabelli Value team Co-Chief Investment Officers Kevin V. Dreyer and Mr. Marangi lead the Fund’s portfolio management during Mr. Gabelli’s absence.
The Gabelli Healthcare & WellnessRx Trust is holding its annual shareholder meeting on May 11, 2026, in Greenwich, Connecticut to elect four trustees. Common and preferred shareholders vote together to elect Mario J. Gabelli, Agnes Mullady and Anthonie C. van Ekris, while preferred shareholders separately elect Vincent D. Enright.
Shareholders of record at the close of business on March 12, 2026 may vote by mail, telephone or Internet, and a quorum requires one‑third of outstanding shares. Large holders include Saba Capital with 14.3% of common shares and GAMCO Investors and affiliates with 77.8% of preferred shares.
Registrant submitted an N‑CEN annual report providing organizational and operational disclosures. The report lists fund governance fields, service providers, broker activity and principal transaction totals. It shows aggregate brokerage commissions of $75,554 and multiple principal transaction line items including $62,513,969, $64,096,883, and $52,994,121.
The filing is a structured annual return of registry information (addresses, directors, advisers, custodians, transfer agents) and specific activity metrics such as commissions paid to brokers and the total value of principal purchases and sales with dealers.
The Gabelli Healthcare & WellnessRx Trust filed its Form N-CSR transmitting the Annual Report for the fiscal year ended December 31, 2025, which includes audited financial statements and the schedule of investments.
Key figures: NAV per common share was $10.53, NAV total return was 1.73%, and investment (market) total return was 6.93%. Total investments at market value were $241,146,682 and net assets attributable to common shareholders were $158,507,330.
Gabelli Healthcare & WellnessRx Trust reported insider activity involving entities associated with Mario J. Gabelli. On January 12, 2026, GGCP, Inc. purchased 3,800 common shares at $9.58 per share, bringing its reported holdings to 316,026 shares. On the same date, Associated Capital Group, Inc. purchased 1,010 common shares at $9.58, bringing its reported holdings to 10,000 shares.
The form also lists 239,425 common shares held directly, plus indirect holdings of 6,380 shares through GPJ Retirement Partners and 3,000 shares in trust accounts. Mario J. Gabelli is a director of the trust and a control person of its adviser, and the disclosure states he disclaims beneficial ownership of shares held by these entities in excess of his indirect pecuniary interest.
Gabelli Healthcare & WellnessRx Trust reported an insider transaction linked to Mario J. Gabelli, a director and control person of the adviser. On January 8, 2026, Associated Capital Group, Inc., an entity associated with him, purchased 990 common shares at $9.58 per share, bringing its reported indirect position to 8,990 shares.
Following this update, Mario J. Gabelli is reported as beneficially owning 239,425 common shares directly, and additional indirect holdings of 312,226 shares through GGCP, Inc., 6,380 shares through GPJ Retirement Partners, LLC, and 3,000 shares through a trust account, with footnotes stating he disclaims beneficial ownership beyond his indirect pecuniary interest in these entities.
Mario J. Gabelli, a director, 10% owner and control person of the adviser to Gabelli Healthcare & WellnessRx Trust, reported multiple transactions in the trust’s Series E Cumulative Preferred Shares dated 12/26/2025. The filing shows open-market or similar purchases of 1,000,000 Series E shares at $10 per share held directly, plus additional purchases of 500,000 shares through Associated Capital Group, Inc., 200,000 shares through GGCP, Inc., and 100,000 shares through MJG Associates, each at $10 per share.
The report also discloses a disposition of 200,000 Series E shares at $10 per share, described as shares surrendered under a contractual “Right to Put to the Fund” for up to 100% of the outstanding Series E preferred. Gabelli disclaims beneficial ownership of shares held by Associated Capital Group and GGCP beyond his indirect pecuniary interest.